Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects
•An accessible and highly concentrated working standard specific for IgG against SARS-CoV-2 Spike-protein was prepared.•The serological SARS-CoV-2 WHO International Standard behaves differently from the working standard produced using sera from vaccinated subjects.•A single instrument-to-instrument...
Saved in:
Published in | Clinica chimica acta Vol. 522; pp. 144 - 151 |
---|---|
Main Authors | , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier B.V
01.11.2021
|
Subjects | |
Online Access | Get full text |
ISSN | 0009-8981 1873-3492 1873-3492 |
DOI | 10.1016/j.cca.2021.08.024 |
Cover
Abstract | •An accessible and highly concentrated working standard specific for IgG against SARS-CoV-2 Spike-protein was prepared.•The serological SARS-CoV-2 WHO International Standard behaves differently from the working standard produced using sera from vaccinated subjects.•A single instrument-to-instrument conversion factors is not sufficient to harmonize different instruments readouts from single samples.•The devices tested performed well in predicting neutralization activity based on the antibody titer.
Vaccines, to limit SARS-CoV-2 infection, were produced and reliable assays are needed for their evaluation. The WHO produced an International-Standard (WHO-IS) to facilitate the standardization/comparison of serological methods. The WHO-IS, produced in limited amount, was never tested for reproducibility. This study aims at developing a reproducible and accessible working standard (WS) to complement the WHO-IS.
Sera from vaccinated individuals were used to produce the WSs. The WHO-IS, the WSs and single serum samples (n = 48) were tested on 6 quantitative serological devices. Neutralization assays were performed for the 48 samples and compared with their antibody titers.
The WS carry an antibody titer 20-fold higher than the WHO-IS. It was reproducible, showed both good linearity and insignificant intra- and inter-laboratory variability. However, the WSs behave differently from the WHO-IS. Analysis of the 48 samples showed that single correlation factors are not sufficient to harmonize results from different assays. Yet, all the devices predict neutralization activity based on the antibody titer.
A reproducible and highly concentrated WS, specific for IgG against SARS-CoV-2 Spike-glycoprotein was produced. Such characteristics make it particularly suited for the harmonization of commercially available assays and the consequent evaluation of post-vaccinated individuals. |
---|---|
AbstractList | •An accessible and highly concentrated working standard specific for IgG against SARS-CoV-2 Spike-protein was prepared.•The serological SARS-CoV-2 WHO International Standard behaves differently from the working standard produced using sera from vaccinated subjects.•A single instrument-to-instrument conversion factors is not sufficient to harmonize different instruments readouts from single samples.•The devices tested performed well in predicting neutralization activity based on the antibody titer.
Vaccines, to limit SARS-CoV-2 infection, were produced and reliable assays are needed for their evaluation. The WHO produced an International-Standard (WHO-IS) to facilitate the standardization/comparison of serological methods. The WHO-IS, produced in limited amount, was never tested for reproducibility. This study aims at developing a reproducible and accessible working standard (WS) to complement the WHO-IS.
Sera from vaccinated individuals were used to produce the WSs. The WHO-IS, the WSs and single serum samples (n = 48) were tested on 6 quantitative serological devices. Neutralization assays were performed for the 48 samples and compared with their antibody titers.
The WS carry an antibody titer 20-fold higher than the WHO-IS. It was reproducible, showed both good linearity and insignificant intra- and inter-laboratory variability. However, the WSs behave differently from the WHO-IS. Analysis of the 48 samples showed that single correlation factors are not sufficient to harmonize results from different assays. Yet, all the devices predict neutralization activity based on the antibody titer.
A reproducible and highly concentrated WS, specific for IgG against SARS-CoV-2 Spike-glycoprotein was produced. Such characteristics make it particularly suited for the harmonization of commercially available assays and the consequent evaluation of post-vaccinated individuals. Vaccines, to limit SARS-CoV-2 infection, were produced and reliable assays are needed for their evaluation. The WHO produced an International-Standard (WHO-IS) to facilitate the standardization/comparison of serological methods. The WHO-IS, produced in limited amount, was never tested for reproducibility. This study aims at developing a reproducible and accessible working standard (WS) to complement the WHO-IS.BACKGROUND AND AIMSVaccines, to limit SARS-CoV-2 infection, were produced and reliable assays are needed for their evaluation. The WHO produced an International-Standard (WHO-IS) to facilitate the standardization/comparison of serological methods. The WHO-IS, produced in limited amount, was never tested for reproducibility. This study aims at developing a reproducible and accessible working standard (WS) to complement the WHO-IS.Sera from vaccinated individuals were used to produce the WSs. The WHO-IS, the WSs and single serum samples (n = 48) were tested on 6 quantitative serological devices. Neutralization assays were performed for the 48 samples and compared with their antibody titers.MATERIALS AND METHODSSera from vaccinated individuals were used to produce the WSs. The WHO-IS, the WSs and single serum samples (n = 48) were tested on 6 quantitative serological devices. Neutralization assays were performed for the 48 samples and compared with their antibody titers.The WS carry an antibody titer 20-fold higher than the WHO-IS. It was reproducible, showed both good linearity and insignificant intra- and inter-laboratory variability. However, the WSs behave differently from the WHO-IS. Analysis of the 48 samples showed that single correlation factors are not sufficient to harmonize results from different assays. Yet, all the devices predict neutralization activity based on the antibody titer.RESULTSThe WS carry an antibody titer 20-fold higher than the WHO-IS. It was reproducible, showed both good linearity and insignificant intra- and inter-laboratory variability. However, the WSs behave differently from the WHO-IS. Analysis of the 48 samples showed that single correlation factors are not sufficient to harmonize results from different assays. Yet, all the devices predict neutralization activity based on the antibody titer.A reproducible and highly concentrated WS, specific for IgG against SARS-CoV-2 Spike-glycoprotein was produced. Such characteristics make it particularly suited for the harmonization of commercially available assays and the consequent evaluation of post-vaccinated individuals.CONCLUSIONSA reproducible and highly concentrated WS, specific for IgG against SARS-CoV-2 Spike-glycoprotein was produced. Such characteristics make it particularly suited for the harmonization of commercially available assays and the consequent evaluation of post-vaccinated individuals. |
Author | Criscuolo, Elena Di Resta, Chiara Perno, Carlo Federico Spanò, Sestina Maria Mancini, Nicasio Ferrari, Davide Tomaiuolo, Rossella Banfi, Giuseppe Viganó, Marco Locatelli, Massimo Albitar-Nehme, Sami Clementi, Nicola Ranno, Stefania Colombini, Alessandra Mangia, Alessandra De Vecchi, Elena |
Author_xml | – sequence: 1 givenname: Davide surname: Ferrari fullname: Ferrari, Davide email: davide.ferrari@unipr.it organization: SCVSA Department, University of Parma, 43121 Parma, Italy – sequence: 2 givenname: Nicola surname: Clementi fullname: Clementi, Nicola organization: Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University, 20158 Milan, Italy – sequence: 3 givenname: Sestina Maria surname: Spanò fullname: Spanò, Sestina Maria organization: IRCCS Orthopedic Institute Galeazzi, Laboratory of Clinical Chemistry and Microbiology, 20161 Milan, Italy – sequence: 4 givenname: Sami surname: Albitar-Nehme fullname: Albitar-Nehme, Sami organization: Microbiology and Immunology Diagnostics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy – sequence: 5 givenname: Stefania surname: Ranno fullname: Ranno, Stefania organization: Microbiology and Immunology Diagnostics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy – sequence: 6 givenname: Alessandra surname: Colombini fullname: Colombini, Alessandra organization: IRCCS Orthopedic Institute Galeazzi, Laboratorio di Biotecnologie Applicate all'Ortopedia, Milan, Italy – sequence: 7 givenname: Elena surname: Criscuolo fullname: Criscuolo, Elena organization: Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University, 20158 Milan, Italy – sequence: 8 givenname: Chiara surname: Di Resta fullname: Di Resta, Chiara organization: IRCCS Ospedale San Raffaele, 20158 Milan, Italy – sequence: 9 givenname: Rossella surname: Tomaiuolo fullname: Tomaiuolo, Rossella organization: Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University, 20158 Milan, Italy – sequence: 10 givenname: Marco surname: Viganó fullname: Viganó, Marco organization: IRCCS Orthopedic Institute Galeazzi, Laboratorio di Biotecnologie Applicate all'Ortopedia, Milan, Italy – sequence: 11 givenname: Nicasio surname: Mancini fullname: Mancini, Nicasio organization: Laboratory of Microbiology and Virology, Vita-Salute San Raffaele University, 20158 Milan, Italy – sequence: 12 givenname: Elena surname: De Vecchi fullname: De Vecchi, Elena organization: IRCCS Orthopedic Institute Galeazzi, Laboratory of Clinical Chemistry and Microbiology, 20161 Milan, Italy – sequence: 13 givenname: Massimo surname: Locatelli fullname: Locatelli, Massimo organization: IRCCS Ospedale San Raffaele, 20158 Milan, Italy – sequence: 14 givenname: Alessandra surname: Mangia fullname: Mangia, Alessandra organization: Liver Unit, Department of Medical Sciences, IRCCS Fondazione, “Casa Sollievo della Sofferenza”, 71013 San Giovanni Rotondo, Italy – sequence: 15 givenname: Carlo Federico surname: Perno fullname: Perno, Carlo Federico organization: Microbiology and Immunology Diagnostics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy – sequence: 16 givenname: Giuseppe surname: Banfi fullname: Banfi, Giuseppe organization: IRCCS Orthopedic Institute Galeazzi, Laboratory of Clinical Chemistry and Microbiology, 20161 Milan, Italy |
BookMark | eNp9kU1r3DAQhkVJaTZpf0BvPvZiRyPLXxQKYUmTQqDQfFzFWB5ttXilRLKXpr--cjYU2kPQYZBmnlfD-56wI-cdMfYReAEc6rNtoTUWggsoeFtwId-wFbRNmZeyE0dsxTnv8rZr4ZidxLhNV8lreMeOSylFBbxaMbzCsPPO_sbJepd5k0X7K3uc0U12Sm97ym7Of9zka3-fiyxS8KPfWI1jhjHiU8zmaN1maeAC71Fr63CiIYtzvyU9xffsrcEx0oeXesruvl7crq_y6--X39bn17mWop3ypgKUfQ2mqTlVGrgRNYiyNelUQLo3ZIaBS4Km6crByKHTiAb7voJK9Lo8ZV8Oug9zv6NBk5sCjuoh2B2GJ-XRqn87zv5UG79Xbdm0vK6SwKcXgeAfZ4qT2tmoaRzRkZ-jElUtoQSo6zQKh1EdfIyBzN9vgKslGrVVKRq1RKN4q1I0iWn-Y_Szw37Zxo6vkp8PJCX79paCitqS0zTYkBxWg7ev0H8ACnerzA |
CitedBy_id | crossref_primary_10_5858_arpa_2021_0604_SA crossref_primary_10_1080_21645515_2023_2215677 crossref_primary_10_3390_vaccines9111357 crossref_primary_10_3390_v14020312 crossref_primary_10_1016_j_cca_2021_09_022 crossref_primary_10_3390_s22145463 crossref_primary_10_1128_spectrum_05353_22 crossref_primary_10_3389_fpubh_2022_847384 crossref_primary_10_3390_vaccines11081380 crossref_primary_10_1002_bimj_202400027 crossref_primary_10_1097_FTD_0000000000000945 crossref_primary_10_1515_cclm_2023_0353 crossref_primary_10_1002_rmv_2451 crossref_primary_10_3389_fimmu_2022_1002576 crossref_primary_10_3390_biomedicines10112892 crossref_primary_10_1111_vox_13480 crossref_primary_10_1515_cclm_2022_0262 crossref_primary_10_1128_spectrum_00597_22 crossref_primary_10_1515_cclm_2022_1161 crossref_primary_10_1002_jcla_24363 crossref_primary_10_3390_vaccines9101092 crossref_primary_10_1016_j_ijid_2022_05_061 crossref_primary_10_7554_eLife_72500 crossref_primary_10_1002_jcla_24306 crossref_primary_10_1016_j_clinbiochem_2023_110681 |
Cites_doi | 10.1111/j.0006-341X.2000.01134.x 10.1093/clinchem/hvab039 10.3390/vaccines9050522 10.1016/j.jcv.2020.104544 10.1093/infdis/jiaa659 10.1016/j.forsciint.2018.04.038 10.1001/jama.2021.3341 10.2217/fvl-2017-0003 10.1016/j.vaccine.2021.06.020 10.1016/S0140-6736(21)00502-X 10.1016/S0140-6736(21)00501-8 10.1056/NEJMc2101667 10.1515/cclm-2021-0023 10.1128/JCM.02511-20 10.1016/j.ebiom.2020.103101 10.1016/j.ijid.2020.12.003 10.1177/000456329703400317 10.1016/j.clim.2020.108634 10.1038/d41573-020-00151-8 |
ContentType | Journal Article |
Copyright | 2021 Elsevier B.V. Copyright © 2021 Elsevier B.V. All rights reserved. 2021 Elsevier B.V. All rights reserved. 2021 Elsevier B.V. |
Copyright_xml | – notice: 2021 Elsevier B.V. – notice: Copyright © 2021 Elsevier B.V. All rights reserved. – notice: 2021 Elsevier B.V. All rights reserved. 2021 Elsevier B.V. |
DBID | AAYXX CITATION 7X8 5PM |
DOI | 10.1016/j.cca.2021.08.024 |
DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry |
EISSN | 1873-3492 |
EndPage | 151 |
ExternalDocumentID | PMC8378065 10_1016_j_cca_2021_08_024 S0009898121003028 |
GroupedDBID | --- --K --M .55 .GJ .~1 0R~ 1B1 1RT 1~. 1~5 29B 4.4 457 4G. 53G 5GY 5VS 6J9 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXUO ABBQC ABFNM ABFRF ABGSF ABJNI ABLVK ABMAC ABMZM ABUDA ABXDB ABYKQ ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AHHHB AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV AJRQY ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC BNPGV CS3 DOVZS DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q G8K GBLVA HLW HVGLF HZ~ IHE J1W J5H K-O KOM L7B LCYCR LX3 M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 R2- RIG RNS ROL RPZ SBG SDF SDG SDP SES SEW SPCBC SSH SSU SSZ T5K WH7 WUQ X7M XPP ZA5 ZGI ~02 ~G- AATTM AAXKI AAYWO AAYXX ABDPE ABWVN ACIEU ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION EFKBS ~HD 7X8 ACLOT 5PM |
ID | FETCH-LOGICAL-c428t-751a4b61f760e5c10f261238f8f851ecbfefdd04e17793df4d9caafabb5152bc3 |
IEDL.DBID | AIKHN |
ISSN | 0009-8981 1873-3492 |
IngestDate | Thu Aug 21 18:11:17 EDT 2025 Sun Sep 28 07:57:32 EDT 2025 Thu Sep 18 00:04:39 EDT 2025 Thu Apr 24 22:55:09 EDT 2025 Fri Feb 23 02:39:45 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | COVID-19 SARS-CoV-2 Serological standard Comirnaty vaccine WHO Neutralization |
Language | English |
License | Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c428t-751a4b61f760e5c10f261238f8f851ecbfefdd04e17793df4d9caafabb5152bc3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8378065 |
PMID | 34425105 |
PQID | 2564131166 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8378065 proquest_miscellaneous_2564131166 crossref_primary_10_1016_j_cca_2021_08_024 crossref_citationtrail_10_1016_j_cca_2021_08_024 elsevier_sciencedirect_doi_10_1016_j_cca_2021_08_024 |
PublicationCentury | 2000 |
PublicationDate | 2021-11-01 |
PublicationDateYYYYMMDD | 2021-11-01 |
PublicationDate_xml | – month: 11 year: 2021 text: 2021-11-01 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | Clinica chimica acta |
PublicationYear | 2021 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Worldometers, COVID-19 statistics. Manisty, Otter, Treibel, McKnight, Altmann, Brooks, Noursadeghi, Boyton, Semper, Moon (b0030) 2021; 397 F. Muecksch, H. Wise, B. Batchelor, M. Squires, E. Semple, C. Richardson, J. McGuire, S. Clearly, E. Furrie, N. Greig, G. Hay, K. Templeton, J.C.C. Lorenzi, T. Hatziioannou, S. Jenks, P.D. Bieniasz, Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients, J. Infect. Dis. 223 (2020) 389–398. doi:10.1093/infdis/jiaa659. Izda, Jeffries, Sawalha (b0010) 2021; 222 F. Krammer, K. Srivastava, P. Team, V. Simon, H. Alshammary, A. Amoako, M. Awawda, K. Beach, C.M. 1 3 Bermúdez-González, D. Bialak, J.M. Carreño, R. Chernet, L. Eaker, E. Ferreri, D. Floda, C. Gleason, J. Hamburger, K. Jiang, G.D. Kleiner, J. Jurczyszak, W. Matthews, L. Mendez, I. Mulder, A. Nabeel, K. Raskin, A. Russo, M. Salimbangon, A. Saksena, G. Shin, L. Singh, D. Sominsky, Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine, N. Engl. J. Med. 384 (2021) 1372-1374. doi: 10.1056/NEJMc2101667. Ferrari, Manca, Premaschi, Banfi, Locatelli (b0105) 2018; 288 C. Di Resta, D. Ferrari, M. Viganò, M. Moro, E. Sabetta, M. Minerva, A. Ambrosio, M. Locatelli, R. Tomaiuolo, The Gender Impact Assessment among Healthcare Workers in the SARS-CoV-2 Vaccination-An Analysis of Serological Response and Side Effects, Vaccines. May 18 (2021) 522. doi:10.3390/vaccines9050522. Le, Cramer, Chen, Mayhew (b0015) 2020; 19 M. Prendecki, C. Clarke, J. Brown, A. Cox, S. Gleeson, M. Guckian, P. Randell, A.D. Pria, L. Lightstone, X.-N. Xu, W. Barclay, S.P. McAdoo, P. Kelleher, M. Willicombe, Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine., Lancet (London, England). 6736 (2021) 10–12. doi:10.1016/S0140-6736(21)00502-X. Ferrari, Di Resta, Tomaiuolo, Sabetta, Pontillo, Motta, Locatelli (b0100) 2021; 39 WHO, Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody, 2020. Bonelli, Blocki, Bunnell, Chu, Arriel De La, Grenache, Marzucchi, Montomoli, Okoye, Pallavicini, Streva, Torelli, Wagner, Zanin, Zierold, Wassenberg (b0055) 2021; 49 Schnurra, Reiners, Biemann, Kaiser, Trawinski, Jassoy (b0065) 2020; 129 2008 (accessed 10 July 2021). Padoan, Bonfante, Pagliari, Bortolami, Negrini, Zuin, Bozzato, Cosma, Sciacovelli, Plebani (b0070) 2020; 62 Centers for Disease Control and Prevention (US), SARS-CoV-2 Variants of Concern, Centers Dis. Control Prev. (2021). https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html#Concern%0Ahttps://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html. (accessed 12 June 2021). Venkatraman (b0115) 2000; 56 C. Therrien, B. Serhir, M. Bélanger-Collard, J. Skrzypczak, D.K. Shank, C. Renaud, J. Girouard, V. Loungnarath, M. Carrier, G. Brochu, F. Tourangeau, B. Gilfix, A. Piche, R. Bazin, R. Guérin, M. Lavoie, V. Martel-Laferrière, C. Fortin, A. Benoit, D. Marcoux, N. Gauthier, A.M. Laumaea, R. Gasser, A. Finzi, M. Roger, Multicenter evaluation of the clinical performance and the neutralizing antibody activity prediction properties of 10 high-throughput serological assays used in clinical laboratories, J. Clin. Microbiol. 59 (2021). doi:10.1128/JCM.02511-20. Tang, Farnsworth (b0060) 2021; 67 2020 (accessed 10 February 2021). S. Saadat, Z.T. Rikhtegaran, L. James, N. Michelle, F. Matthew B., A.D. Harris, M.M. Sajadi, Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health CareWorkers Previously InfectedWith SARS-CoV-2, JAMA - J. Am. Med. Assoc. Mar 1;e213 (2021). doi:10.1001/jama.2021.3341. Kittel, Muth, Zahn, Roth, Thiaucourt, Gerhards, Haselmann, Neumaier, Findeisen (b0050) 2021; 103 World Health Organization, WHO TRS: Recommendations for the preparation, characterization and establishment of international and other biological reference standards, http://www.who.int/immunization_standards/vaccine_reference_preparations/TRS932Annex 2_Inter _biol ef standards rev2004.pdf?ua=1, 2006 (accessed 12 March 2021). Page, Wilkinson, Mattiuzzo, Efstathiou, Minor (b0085) 2017; 12 Payne (b0110) 1997; 34 10.1016/j.cca.2021.08.024_b0005 Schnurra (10.1016/j.cca.2021.08.024_b0065) 2020; 129 Ferrari (10.1016/j.cca.2021.08.024_b0105) 2018; 288 Le (10.1016/j.cca.2021.08.024_b0015) 2020; 19 10.1016/j.cca.2021.08.024_b0020 10.1016/j.cca.2021.08.024_b0075 Tang (10.1016/j.cca.2021.08.024_b0060) 2021; 67 10.1016/j.cca.2021.08.024_b0035 Bonelli (10.1016/j.cca.2021.08.024_b0055) 2021; 49 Venkatraman (10.1016/j.cca.2021.08.024_b0115) 2000; 56 10.1016/j.cca.2021.08.024_b0045 Manisty (10.1016/j.cca.2021.08.024_b0030) 2021; 397 10.1016/j.cca.2021.08.024_b0025 Payne (10.1016/j.cca.2021.08.024_b0110) 1997; 34 10.1016/j.cca.2021.08.024_b0080 10.1016/j.cca.2021.08.024_b0090 Ferrari (10.1016/j.cca.2021.08.024_b0100) 2021; 39 Izda (10.1016/j.cca.2021.08.024_b0010) 2021; 222 10.1016/j.cca.2021.08.024_b0040 10.1016/j.cca.2021.08.024_b0095 Padoan (10.1016/j.cca.2021.08.024_b0070) 2020; 62 Page (10.1016/j.cca.2021.08.024_b0085) 2017; 12 Kittel (10.1016/j.cca.2021.08.024_b0050) 2021; 103 |
References_xml | – volume: 288 start-page: 211 year: 2018 end-page: 217 ident: b0105 article-title: Toxicological investigation in blood samples from suspected impaired driving cases in the Milan area : Possible loss of evidence due to late blood sampling publication-title: Forensic Sci Int. – reference: S. Saadat, Z.T. Rikhtegaran, L. James, N. Michelle, F. Matthew B., A.D. Harris, M.M. Sajadi, Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health CareWorkers Previously InfectedWith SARS-CoV-2, JAMA - J. Am. Med. Assoc. Mar 1;e213 (2021). doi:10.1001/jama.2021.3341. – volume: 62 start-page: 103101 year: 2020 ident: b0070 article-title: Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity publication-title: EBioMedicine. – volume: 56 start-page: 1134 year: 2000 end-page: 1138 ident: b0115 article-title: A permutation test to compare receiver operating characteristic curves publication-title: Biometrics. – reference: Worldometers, COVID-19 statistics. – reference: F. Krammer, K. Srivastava, P. Team, V. Simon, H. Alshammary, A. Amoako, M. Awawda, K. Beach, C.M. 1 3 Bermúdez-González, D. Bialak, J.M. Carreño, R. Chernet, L. Eaker, E. Ferreri, D. Floda, C. Gleason, J. Hamburger, K. Jiang, G.D. Kleiner, J. Jurczyszak, W. Matthews, L. Mendez, I. Mulder, A. Nabeel, K. Raskin, A. Russo, M. Salimbangon, A. Saksena, G. Shin, L. Singh, D. Sominsky, Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine, N. Engl. J. Med. 384 (2021) 1372-1374. doi: 10.1056/NEJMc2101667. – volume: 39 start-page: 4256 year: 2021 end-page: 4260 ident: b0100 article-title: Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects publication-title: Vaccine. – volume: 12 start-page: 431 year: 2017 end-page: 437 ident: b0085 article-title: Developing biological standards for vaccine evaluation publication-title: Future Virol. – volume: 67 start-page: 707 year: 2021 end-page: 709 ident: b0060 article-title: Associating SARS-CoV-2 Serological Assays with Protection: Where the Field Stands publication-title: Clin. Chem. – reference: C. Di Resta, D. Ferrari, M. Viganò, M. Moro, E. Sabetta, M. Minerva, A. Ambrosio, M. Locatelli, R. Tomaiuolo, The Gender Impact Assessment among Healthcare Workers in the SARS-CoV-2 Vaccination-An Analysis of Serological Response and Side Effects, Vaccines. May 18 (2021) 522. doi:10.3390/vaccines9050522. – volume: 222 start-page: 108634 year: 2021 ident: b0010 article-title: COVID-19: A review of therapeutic strategies and vaccine candidates publication-title: Clin. Immunol. – volume: 34 start-page: 319 year: 1997 end-page: 320 ident: b0110 article-title: Method comparison: Evaluation of least squares, Deming and Passing/Bablok regression procedures using computer simulation publication-title: Ann. Clin. Biochem. – reference: F. Muecksch, H. Wise, B. Batchelor, M. Squires, E. Semple, C. Richardson, J. McGuire, S. Clearly, E. Furrie, N. Greig, G. Hay, K. Templeton, J.C.C. Lorenzi, T. Hatziioannou, S. Jenks, P.D. Bieniasz, Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients, J. Infect. Dis. 223 (2020) 389–398. doi:10.1093/infdis/jiaa659. – volume: 19 start-page: 667 year: 2020 end-page: 668 ident: b0015 article-title: Evolution of the COVID-19 vaccine development landscape publication-title: Nat. Rev. Drug Discov. – reference: C. Therrien, B. Serhir, M. Bélanger-Collard, J. Skrzypczak, D.K. Shank, C. Renaud, J. Girouard, V. Loungnarath, M. Carrier, G. Brochu, F. Tourangeau, B. Gilfix, A. Piche, R. Bazin, R. Guérin, M. Lavoie, V. Martel-Laferrière, C. Fortin, A. Benoit, D. Marcoux, N. Gauthier, A.M. Laumaea, R. Gasser, A. Finzi, M. Roger, Multicenter evaluation of the clinical performance and the neutralizing antibody activity prediction properties of 10 high-throughput serological assays used in clinical laboratories, J. Clin. Microbiol. 59 (2021). doi:10.1128/JCM.02511-20. – reference: , 2008 (accessed 10 July 2021). – reference: World Health Organization, WHO TRS: Recommendations for the preparation, characterization and establishment of international and other biological reference standards, http://www.who.int/immunization_standards/vaccine_reference_preparations/TRS932Annex 2_Inter _biol ef standards rev2004.pdf?ua=1, 2006 (accessed 12 March 2021). – volume: 103 start-page: 590 year: 2021 end-page: 596 ident: b0050 article-title: Clinical evaluation of commercial automated SARS-CoV-2 immunoassays publication-title: Int. J. Infect. Dis. – reference: Centers for Disease Control and Prevention (US), SARS-CoV-2 Variants of Concern, Centers Dis. Control Prev. (2021). https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html#Concern%0Ahttps://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html. (accessed 12 June 2021). – volume: 397 start-page: 1057 year: 2021 end-page: 1058 ident: b0030 article-title: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals publication-title: Lancet – reference: M. Prendecki, C. Clarke, J. Brown, A. Cox, S. Gleeson, M. Guckian, P. Randell, A.D. Pria, L. Lightstone, X.-N. Xu, W. Barclay, S.P. McAdoo, P. Kelleher, M. Willicombe, Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine., Lancet (London, England). 6736 (2021) 10–12. doi:10.1016/S0140-6736(21)00502-X. – reference: WHO, Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody, 2020. – reference: , 2020 (accessed 10 February 2021). – volume: 49 start-page: 1463 year: 2021 end-page: 1467 ident: b0055 article-title: Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies publication-title: Clin. Chem. Lab. Med. – volume: 129 start-page: 104544 year: 2020 ident: b0065 article-title: Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests publication-title: J. Clin. Virol. – volume: 56 start-page: 1134 year: 2000 ident: 10.1016/j.cca.2021.08.024_b0115 article-title: A permutation test to compare receiver operating characteristic curves publication-title: Biometrics. doi: 10.1111/j.0006-341X.2000.01134.x – volume: 67 start-page: 707 year: 2021 ident: 10.1016/j.cca.2021.08.024_b0060 article-title: Associating SARS-CoV-2 Serological Assays with Protection: Where the Field Stands publication-title: Clin. Chem. doi: 10.1093/clinchem/hvab039 – ident: 10.1016/j.cca.2021.08.024_b0040 doi: 10.3390/vaccines9050522 – volume: 129 start-page: 104544 year: 2020 ident: 10.1016/j.cca.2021.08.024_b0065 article-title: Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests publication-title: J. Clin. Virol. doi: 10.1016/j.jcv.2020.104544 – ident: 10.1016/j.cca.2021.08.024_b0075 – ident: 10.1016/j.cca.2021.08.024_b0090 doi: 10.1093/infdis/jiaa659 – volume: 288 start-page: 211 year: 2018 ident: 10.1016/j.cca.2021.08.024_b0105 article-title: Toxicological investigation in blood samples from suspected impaired driving cases in the Milan area : Possible loss of evidence due to late blood sampling publication-title: Forensic Sci Int. doi: 10.1016/j.forsciint.2018.04.038 – ident: 10.1016/j.cca.2021.08.024_b0095 – ident: 10.1016/j.cca.2021.08.024_b0035 doi: 10.1001/jama.2021.3341 – volume: 12 start-page: 431 issue: 8 year: 2017 ident: 10.1016/j.cca.2021.08.024_b0085 article-title: Developing biological standards for vaccine evaluation publication-title: Future Virol. doi: 10.2217/fvl-2017-0003 – volume: 39 start-page: 4256 issue: 31 year: 2021 ident: 10.1016/j.cca.2021.08.024_b0100 article-title: Long-term antibody persistence and exceptional vaccination response on previously SARS-CoV-2 infected subjects publication-title: Vaccine. doi: 10.1016/j.vaccine.2021.06.020 – ident: 10.1016/j.cca.2021.08.024_b0025 doi: 10.1016/S0140-6736(21)00502-X – volume: 397 start-page: 1057 issue: 10279 year: 2021 ident: 10.1016/j.cca.2021.08.024_b0030 article-title: Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals publication-title: Lancet doi: 10.1016/S0140-6736(21)00501-8 – ident: 10.1016/j.cca.2021.08.024_b0020 doi: 10.1056/NEJMc2101667 – volume: 49 start-page: 1463 year: 2021 ident: 10.1016/j.cca.2021.08.024_b0055 article-title: Evaluation of the automated LIAISON® SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies publication-title: Clin. Chem. Lab. Med. doi: 10.1515/cclm-2021-0023 – ident: 10.1016/j.cca.2021.08.024_b0045 doi: 10.1128/JCM.02511-20 – volume: 62 start-page: 103101 year: 2020 ident: 10.1016/j.cca.2021.08.024_b0070 article-title: Analytical and clinical performances of five immunoassays for the detection of SARS-CoV-2 antibodies in comparison with neutralization activity publication-title: EBioMedicine. doi: 10.1016/j.ebiom.2020.103101 – volume: 103 start-page: 590 year: 2021 ident: 10.1016/j.cca.2021.08.024_b0050 article-title: Clinical evaluation of commercial automated SARS-CoV-2 immunoassays publication-title: Int. J. Infect. Dis. doi: 10.1016/j.ijid.2020.12.003 – ident: 10.1016/j.cca.2021.08.024_b0005 – ident: 10.1016/j.cca.2021.08.024_b0080 – volume: 34 start-page: 319 issue: 3 year: 1997 ident: 10.1016/j.cca.2021.08.024_b0110 article-title: Method comparison: Evaluation of least squares, Deming and Passing/Bablok regression procedures using computer simulation publication-title: Ann. Clin. Biochem. doi: 10.1177/000456329703400317 – volume: 222 start-page: 108634 year: 2021 ident: 10.1016/j.cca.2021.08.024_b0010 article-title: COVID-19: A review of therapeutic strategies and vaccine candidates publication-title: Clin. Immunol. doi: 10.1016/j.clim.2020.108634 – volume: 19 start-page: 667 issue: 10 year: 2020 ident: 10.1016/j.cca.2021.08.024_b0015 article-title: Evolution of the COVID-19 vaccine development landscape publication-title: Nat. Rev. Drug Discov. doi: 10.1038/d41573-020-00151-8 |
SSID | ssj0004061 |
Score | 2.4883957 |
Snippet | •An accessible and highly concentrated working standard specific for IgG against SARS-CoV-2 Spike-protein was prepared.•The serological SARS-CoV-2 WHO... Vaccines, to limit SARS-CoV-2 infection, were produced and reliable assays are needed for their evaluation. The WHO produced an International-Standard (WHO-IS)... |
SourceID | pubmedcentral proquest crossref elsevier |
SourceType | Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
StartPage | 144 |
SubjectTerms | Comirnaty vaccine COVID-19 Neutralization SARS-CoV-2 Serological standard WHO |
Title | Harmonization of six quantitative SARS-CoV-2 serological assays using sera of vaccinated subjects |
URI | https://dx.doi.org/10.1016/j.cca.2021.08.024 https://www.proquest.com/docview/2564131166 https://pubmed.ncbi.nlm.nih.gov/PMC8378065 |
Volume | 522 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8MwDLZgSMAF8RTjpSBxQiq0WfrgOE2gAYIDL3GLkjaBIdQB3RBc-O3YawLsAAfUU5s6SmPHsRv7M8AOj1R8YOI8SFLLA4EuM-pBkQY2M4lBf6EQlhKFz86T7rU4uY1vJ6Djc2EorNLp_lqnj7S1e7LvZnP_qdejHN-Qih8SAhZKKs8mYYrjbp81YKp9fNo9_06PDJPIF1QjAn-4OQrzwi9AL5HXQJ5c_LY9_TA_x4Mnf-xGR_Mw58xI1q5HugATplyEmY6v3rYI02fu0HwJVFe9oLC5hEvWt6zqvbHnoSpHCWao7thl--Iy6PRvAs5QJL0-ZGhYq_eKUWz8HTUoIn5VOfaLJmrBqqGm3zjVMlwfHV51uoGrrBDk6G4MgjSOlNBJZNMkREZFoSUksVZm8Yojk2trbFGEwkQprt_CiuIgV8oqrdH84TpvrUCj7JdmFZjIcAVbdIsKa4UWucJOuY6JwhRxqpoQ-gmVuYMdp-oXj9LHlz1I5IEkHkiqiMlFE3a_SJ5qzI2_XhaeS3JMcCTuCX-RbXuOSuQMnZKo0vSHlUQbUBAGUZI0IR1j9ddgCJJ7vKXs3Y-guQmeH426tf8Nah1m6a5OddyAxuBlaDbR5hnoLZjc-4i2nGR_AvGgAss |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwEB5BkYDLiqe27AJG4oQUkbhO0h6riio82gMvcbPsxIaiVQqkRbv_fmcaG-gBDii3OBM5mcn4m3jmG4BDHqm4Y-I8SFLLA4EhM_pBkQa2bRKD8UIhLBUKD4ZJdiPO7uK7Bej5WhhKq3S-v_bpM2_tzhy7t3n8NBpRjW9IzQ-JAQstlbcXYUlQU-sGLHVPz7Phe3lkmES-oRoJ-M3NWZoXPgFGibwm8uTis-XpA_ycT578sBr11-CHg5GsW890HRZMuQErPd-9bQOWB27TfBNUpl7Q2FzBJRtbVo3-suepKmcFZuju2FX38irojW8DztAkvT9kCKzVv4pRbvw9DSgSflU53hchasGqqabfONUW3PRPrntZ4DorBDmGG5MgjSMldBLZNAlRUVFoiUms1bZ4xJHJtTW2KEJhohS_38KKopMrZZXWCH-4zlvb0CjHpfkJTLTxC7YYFhXWCi1yhTflOiYJU8SpakLoX6jMHe04db_4I31-2aNEHUjSgaSOmFw04ehN5Knm3PjqYuG1JOcMR-Ka8JXYgdeoRM3QLokqzXhaScSAgjiIkqQJ6Zyq3yZDlNzzI-XoYUbNTfT8COp2vjepfVjJrgcX8uJ0eP4LVmmkLnv8DY3Jy9TsIv6Z6D1n3_8BCjEEsQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Harmonization+of+six+quantitative+SARS-CoV-2+serological+assays+using+sera+of+vaccinated+subjects&rft.jtitle=Clinica+chimica+acta&rft.au=Ferrari%2C+Davide&rft.au=Clementi%2C+Nicola&rft.au=Span%C3%B2%2C+Sestina+Maria&rft.au=Albitar-Nehme%2C+Sami&rft.date=2021-11-01&rft.issn=1873-3492&rft.eissn=1873-3492&rft.volume=522&rft.spage=144&rft_id=info:doi/10.1016%2Fj.cca.2021.08.024&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-8981&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-8981&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-8981&client=summon |